New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value
Lupin will address the observations and respond to the U.S. FDA within the stipulated timeframe
Combination creates a leading, next generation claims operating system for payers, with end-to-end AI capabilities for claims, payments, care & utilization management, payment integrity, and member engagement, serving 115+ health plans
Vonvendi is the only recombinant Von Willebrand factor replacement therapy with approved indications in adults and children with VWD
The U.S. FDA issued a Form 483 with five observations
Under the terms of this agreement, Synthon will be responsible for obtaining final regulatory approval for its Ozanimod Capsules product
Now integrates with Abbott’s instinct sensor and approved for type 2 diabetes
This is Lupin's first product using proprietary Nanomi's technology and has a 180-day CGT exclusivity
Free cash flow also reached €63 million, representing an 11 percent increase compared to the high benchmark set in 2024
New targeted therapy offers hope for patients with unresectable or metastatic NSCLC harboring HER2 tyrosine kinase domain activating mutations
Subscribe To Our Newsletter & Stay Updated
